Blood plasma biomarkers improve prediction accuracy over and above genetic predictors of Alzheimer’s disease

Prediction models of Alzheimer’s disease using genetic information, such as polygenic risk scores, have been able to reach high levels of prediction accuracy. However, since confirmation of the disease is only possible post‐mortem, these levels of prediction accuracy are typically only achievable in pathologically confirmed cohorts. In living individuals who have been clinically assessed for AD, prediction accuracy by genetics is still good but much lower. Biomarkers can indirectly assess AD pathologies, and so may be able to bridge the prediction accuracy gap. Blood plasma biomarkers may have additional clinical utility as they are cheaper and more accessible compared to traditional CSF or PET methods.